Literature DB >> 26294634

Complete Genome Sequence of the Nonpathogenic Soil-Dwelling Bacterium Clostridium sporogenes Strain NCIMB 10696.

Aleksandra M Kubiak1, Anja Poehlein2, Patrick Budd1, Sarah A Kuehne1, Klaus Winzer1, Jan Theys3, Philip Lambin3, Rolf Daniel2, Nigel P Minton4.   

Abstract

Clostridium sporogenes is a harmless spore-forming anaerobe that is widely distributed in soil/water and in the intestines of humans and animals. It is extensively used as a safe model to test the suitability of new preservative methods by the food industry and has potential to deliver therapeutic agents to tumors.
Copyright © 2015 Kubiak et al.

Entities:  

Year:  2015        PMID: 26294634      PMCID: PMC4543512          DOI: 10.1128/genomeA.00942-15

Source DB:  PubMed          Journal:  Genome Announc


GENOME ANNOUNCEMENT

Clostridium sporogenes NCIMB 10696 has the potential to be a tumor delivery vehicle for therapeutic agents (1, 2). It is classified by the UK Advisory Committee on Dangerous Pathogens as a harmless group I organism and by the American Type Culture Collection (ATCC 3584) as a harmless biosafety level 1 organism. Its categorization as safe is further demonstrated by the routine use of its spores by the food industry to assess the effectiveness of food preservation methods (3). While closely related to Clostridium botulinum, C. sporogenes does not produce botulinum toxin and differs markedly with regard to sporulation kinetics (4). Genomic DNA was prepared by phenol-chloroform extraction (5) and sequenced using the 454 Titanium FLX (Roche Diagnostics) with 3 separate paired-end read sequencing libraries. Genomic DNA was also Illumina resequenced by GATC Biotech (Germany). The sequencing data (1,983,599 reads) were assembled using the GS assembler (Newbler 2.3) into 54 contigs (>500 bp) with a total size of 4,080,182 bp providing 74× coverage. The average contig length was 75,558 bp and the average scaffold size of 682,834 bp, with the largest scaffold being 3,498,261 bp. A total of 39 contig gaps within scaffolds were closed using standard PCR procedures, leading to a draft genome of 4,087,164 bp composed of 5 large scaffolds. Scaffold order was predicted using the move contigs tool of the Mauve Genome Alignment Software (6) and via Gene Ortholog Neighborhoods based on bidirectional best hits implemented at the IMG-ER (Integrated Microbial Genomes/Expert Review) system (7). Alignments were performed using the genomes of C. sporogenes ATCC 15579 (GenBank accession number ABKW00000000), C. botulinum ATCC 3502, and C. botulinum BoNT/B1 Okra (accession number CP000939) as references. A repeat of the assembly was carried out using the Newbler and Mira v3.4 packages and additional Sanger dideoxy sequencing. The final genome sequence length is 4,141,984 bp with an average coverage of 115×. Gene prediction was performed using the software tool Prodigal (8). Genes encoding rRNA and tRNA were identified using RNAmmer (9) and tRNAscan (10), respectively. The IMG/ER (Integrated Microbial Genomes/Expert Review) system (7) was used for automatic annotation. Subsequent manual curation used the Swiss-Prot, TREMBL, and InterPro databases (11). The number of annotated features are coding sequence (CDS), 3,732; protein-encoding genes with function prediction, 2,956; putative genes coding for hypothetical proteins, 776; pseudogenes, 4; rRNA clusters, 9 (27 genes); and tRNA, 80. The G+C content was 27.98%, and 82% of the genome was encoding. BLAST comparison revealed a 97 to 100% match to other C. sporogenes species and 91 to 99% to proteolytic C. botulinum strains (12, 13). The 16S rRNA gene sequences of C. botulinum and C. sporogenes strains share 99 to 100% nucleotide similarity. The assembly and annotation did not reveal the presence of any induced prophages or plasmids. BLAST and PCR analysis of the major toxins produced by C. botulinum (groups I through IV) demonstrated that no toxin-encoding genes or remnants are present, highlighting the nonpathogenic nature of C. sporogenes NCIMB 10696 and supporting its use in clostridial-directed enzyme prodrug therapy (CDEPT) (14, 15).

Nucleotide sequence accession number.

The genome sequence is deposited at GenBank under the accession number CP009225.
  14 in total

Review 1.  Control of bacterial spores.

Authors:  K L Brown
Journal:  Br Med Bull       Date:  2000       Impact factor: 4.291

2.  InterProScan--an integration platform for the signature-recognition methods in InterPro.

Authors:  E M Zdobnov; R Apweiler
Journal:  Bioinformatics       Date:  2001-09       Impact factor: 6.937

3.  tRNAscan-SE: a program for improved detection of transfer RNA genes in genomic sequence.

Authors:  T M Lowe; S R Eddy
Journal:  Nucleic Acids Res       Date:  1997-03-01       Impact factor: 16.971

4.  Draft genome sequence of Clostridium sporogenes PA 3679, the common nontoxigenic surrogate for proteolytic Clostridium botulinum.

Authors:  Mark Bradbury; Paul Greenfield; David Midgley; Dongmei Li; Nai Tran-Dinh; Frank Vriesekoop; Janelle L Brown
Journal:  J Bacteriol       Date:  2012-03       Impact factor: 3.490

Review 5.  The potential of clostridial spores as therapeutic delivery vehicles in tumour therapy.

Authors:  Aleksandra M Kubiak; Nigel P Minton
Journal:  Res Microbiol       Date:  2015-01-07       Impact factor: 3.992

6.  Prodigal: prokaryotic gene recognition and translation initiation site identification.

Authors:  Doug Hyatt; Gwo-Liang Chen; Philip F Locascio; Miriam L Land; Frank W Larimer; Loren J Hauser
Journal:  BMC Bioinformatics       Date:  2010-03-08       Impact factor: 3.169

7.  Synergistic inactivation of spores of proteolytic Clostridium botulinum strains by high pressure and heat is strain and product dependent.

Authors:  M K Bull; S A Olivier; R J van Diepenbeek; F Kormelink; B Chapman
Journal:  Appl Environ Microbiol       Date:  2008-11-14       Impact factor: 4.792

Review 8.  Clostridia in cancer therapy.

Authors:  Nigel P Minton
Journal:  Nat Rev Microbiol       Date:  2003-12       Impact factor: 60.633

9.  Genome sequence of a proteolytic (Group I) Clostridium botulinum strain Hall A and comparative analysis of the clostridial genomes.

Authors:  Mohammed Sebaihia; Michael W Peck; Nigel P Minton; Nicholas R Thomson; Matthew T G Holden; Wilfrid J Mitchell; Andrew T Carter; Stephen D Bentley; David R Mason; Lisa Crossman; Catherine J Paul; Alasdair Ivens; Marjon H J Wells-Bennik; Ian J Davis; Ana M Cerdeño-Tárraga; Carol Churcher; Michael A Quail; Tracey Chillingworth; Theresa Feltwell; Audrey Fraser; Ian Goodhead; Zahra Hance; Kay Jagels; Natasha Larke; Mark Maddison; Sharon Moule; Karen Mungall; Halina Norbertczak; Ester Rabbinowitsch; Mandy Sanders; Mark Simmonds; Brian White; Sally Whithead; Julian Parkhill
Journal:  Genome Res       Date:  2007-05-22       Impact factor: 9.043

10.  Spores of Clostridium engineered for clinical efficacy and safety cause regression and cure of tumors in vivo.

Authors:  John T Heap; Jan Theys; Muhammad Ehsaan; Aleksandra M Kubiak; Ludwig Dubois; Kim Paesmans; Lieve Van Mellaert; Richard Knox; Sarah A Kuehne; Phillipe Lambin; Nigel P Minton
Journal:  Oncotarget       Date:  2014-04-15
View more
  2 in total

1.  A novel conjugal donor strain for improved DNA transfer into Clostridium spp.

Authors:  Craig Woods; Christopher M Humphreys; Raquel Mesquita Rodrigues; Patrick Ingle; Peter Rowe; Anne M Henstra; Michael Köpke; Sean D Simpson; Klaus Winzer; Nigel P Minton
Journal:  Anaerobe       Date:  2019-06-30       Impact factor: 3.331

2.  Recombinant expression and characterisation of the oxygen-sensitive 2-enoate reductase from Clostridium sporogenes.

Authors:  Pawel M Mordaka; Stephen J Hall; Nigel Minton; Gill Stephens
Journal:  Microbiology (Reading)       Date:  2017-11-07       Impact factor: 2.777

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.